Combination therapy for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of three drugs (chidamide, toripalimab, and anlotinib) for nasopharyngeal cancer that has come back or spread after a previous treatment. It may be an option if you have already tried immunotherapy for at least 6 months and your disease was controlled.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your nasopharyngeal cancer has spread and did not respond to at least one prior chemotherapy treatment.
- You have previously received a type of immunotherapy (like PD-1 inhibitors) and your tumor either shrank or stayed stable for at least 6 months.
- You have not been treated before with an HDAC inhibitor (like chidamide) or an anti-angiogenic drug (like anlotinib).
- Your overall health is good enough to be up and about (ECOG 0 or 1), and your organs (like bone marrow, liver, kidneys) are working well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination treatment (chemotherapy before, then chemotherapy with radiation) for advanced nasopharyngeal cancer that hasn't spread to distant sites. The goal is to improve survival and control of the disease.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
This trial studies whether adding an anti–PD-1 immunotherapy to standard chemoradiotherapy can control nasopharyngeal cancer that has come back in the local area. It may help patients live longer or have the cancer respond better compared with chemoradiotherapy alone.
This trial tests a combination of three drugs (MRG003, capecitabine, and a PD-1 inhibitor) for nasopharyngeal cancer that has come back only in the same area. The goal is to see if this combination can shrink the tumor and prevent it from coming back.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.